|
Dan Wozniak, PhDCo-Director, C3 P&F ProgramDr. Wozniak is a nationally recognized leader in CF training, having served as a standing member of the Cystic Fibrosis Foundation Research and Research Training Committee for 10 years. He has trained 22 PhD students and 11 postdoctoral fellows, each having established independent careers in biomedical sciences.
|
|
Sriram Vaidyanathan, PhDCo-Director, C3 P&F ProgramSriram Vaidyanathan, PhD, is a principal investigator in the Jerry R. Mendell Center for Gene Therapy at the Abigail Wexner Research Institute at Nationwide Children’s Hospital and an assistant professor of Pediatrics at The Ohio State University College of Medicine. Dr. Vaidyanathan earned his bachelor’s degree in biomedical engineering from Purdue University and his doctorate in biomedical engineering from the University of Michigan, Ann Arbor. He completed his postdoctoral training with Dr. Matthew Porteus at Stanford University, CA. His primary research interest has been the development of gene and cell therapies. His most recent work has been focused on the development of CRISPR/Cas9 based genome editing to treat cystic fibrosis (CF). His lab will continue to further develop genome editing approaches to treat CF and other airway diseases.
|
Current Supported P&F Projects
|
|
2024 Supported P&F Projects
|
Local Airway Mechanical Preconditioning for Gene-Corrected Airway Basal Cells
|
|
The Use of Nitric Oxide Delivered Using Engineered Upper Airway Cells to Combat Severe Infections in People with Cystic Fibrosis
|
2023 Supported P&F Projects
|
Testing a humanized monoclonal antibody directed at targeted protective domains of the bacterial DNABII proteins to disrupt nontuberculous mycobacteria (NTM) biofilms and render the newly released bacteria vulnerable to amikacin-mediated killing
|
|
The Use of Nitric Oxide Delivered Using Engineered Upper Airway Cells to Combat Severe Infections in People with Cystic Fibrosis
|
2022 Supported P&F Projects
|
Emily Hemann, PhD
|
Challenges and Opportunities of Adaptive Immunity in CF
|
|
Lauren Bakaletz, PhD
|
Testing a humanized monoclonal antibody directed at targeted protective domains of the bacterial DNABII proteins to disrupt nontuberculous mycobacteria (NTM) biofilms and render the newly released bacteria vulnerable to amikacin-mediated killing
|
2021 Supported P&F Projects
|
Murugesan Rajaram, PhD
|
Molecular mechanism of cardiac dysfunction during infection in CF
|
|
Erin Gloag, PhD
|
Biofilm Viscoelasticity as an Adaptive Survival Strategy in the CF Lung
|
2019 Supported P&F Projects
|
Prosper Boyaka, PhD
|
Adaptive Immunity in CF: Understanding B Cell Function
|
|
Richard Robinson, PhD
|
T Cell Dysfunction in CF Patients with Nontuberculous Mycobacteria
|
2018 Supported P&F Projects
|
Luanne Hall-Stoodley, PhD
|
The Role of Autophagy in Defective Mycobacterium Abscessus Clearance in CF Macrophages
|
|
Don Hayes Jr, MD
|
Epithelial Cell Chimerism in Cystic Fibrosis Lung Transplant Recipients
|
|
Mark Hester, PhD
|
Effects of CFTR Modulation on Mental Health and the NAA Pathway in Cystic Fibrosis
|
|
Houchon Harry Hu, PhD
|
Magnetic Resonance Elastography and 3D Printing in Cystic Fibrosis
|
|
Benjamin Kopp, MD, MPH
|
Role of CFTR and ENaC in Macrophage-Mediated Bacterial Killing
|
|
Maria Talavera, DO
|
The Role of DUSP6 in CF-Associated Intestinal Inflammation
|
|
Daniel Wozniak, PhDDirector, C3 P&F Program
Dr. Wozniak is a nationally recognized leader in CF training, serving as a standing member of the Cystic Fibrosis Foundation Research and Research Training Committee since 2008. He has trained 16 PhD students and 7 postdoctoral fellows, each having established independent careers in biomedical sciences.
|